Soligenix Strengthens Medical Advisory Board to Advance HyBryte CTCL Treatment Through Phase 3 Development
Soligenix has updated its U.S. Medical Advisory Board with leading dermatologic and oncologic experts to guide the Phase 3 development and potential commercialization of HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma that addresses significant unmet medical needs.
Soligenix Inc. has announced updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma to support the ongoing Phase 3 development of HyBryte, the company's synthetic hypericin photodynamic therapy. The board, comprised of leading dermatologic and oncologic experts, will provide strategic guidance as Soligenix advances regulatory and commercialization activities for its innovative treatment approach. This development represents a significant step forward in addressing the unmet medical needs of CTCL patients worldwide.
President and CEO Christopher J. Schaber emphasized that the addition of new key opinion leaders reinforces the program's clinical depth and demonstrates the company's commitment to bringing HyBryte to patients suffering from this rare disease. The advisory board's expertise will be crucial in navigating the complex regulatory landscape and preparing for potential commercialization following successful completion of the second Phase 3 study. The full details of this announcement are available in the company's official press release at https://ibn.fm/R32rm.
HyBryte represents a novel approach to treating CTCL through photodynamic therapy utilizing safe visible light. The treatment's development is particularly important given the limited therapeutic options currently available for this rare form of lymphoma that primarily affects the skin. With the successful completion of the second Phase 3 study, Soligenix plans to seek regulatory approvals to support potential commercialization worldwide, potentially offering new hope for patients with this challenging condition.
The significance of this development extends beyond the immediate CTCL application, as Soligenix is also exploring expansion of synthetic hypericin into psoriasis treatment. This broader therapeutic potential underscores the importance of the medical advisory board's guidance in maximizing the treatment's clinical impact across multiple dermatological conditions. The company maintains an active newsroom where investors and stakeholders can follow ongoing developments at https://ibn.fm/SNGX.
Soligenix's approach to HyBryte development reflects the growing emphasis on targeted therapies for rare diseases where conventional treatments often fall short. The medical advisory board's involvement ensures that clinical development remains aligned with real-world patient needs and treatment standards. As the program advances through Phase 3 development, the board's strategic input will be instrumental in shaping both the regulatory pathway and eventual market access strategies for this promising therapy.